Compare BLTE & LW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | LW |
|---|---|---|
| Founded | 2018 | 1950 |
| Country | United States | United States |
| Employees | N/A | 10100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.7B |
| IPO Year | 2021 | 2016 |
| Metric | BLTE | LW |
|---|---|---|
| Price | $158.49 | $43.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 7 |
| Target Price | ★ $198.00 | $44.14 |
| AVG Volume (30 Days) | 117.4K | ★ 2.1M |
| Earning Date | 05-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | ★ 3.53% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.26 |
| Revenue Next Year | $492.11 | N/A |
| P/E Ratio | ★ N/A | $33.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.68 | $37.62 |
| 52 Week High | $200.00 | $67.07 |
| Indicator | BLTE | LW |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 52.52 |
| Support Level | $157.63 | $39.70 |
| Resistance Level | $161.28 | $46.61 |
| Average True Range (ATR) | 6.26 | 1.42 |
| MACD | -1.15 | 0.04 |
| Stochastic Oscillator | 17.27 | 45.70 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Lamb Weston is North America's largest and the world's second-largest producer of branded and private-label frozen potato products, both by volume and value. The company's portfolio is anchored by french fries, but it also sells sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. Roughly two thirds of revenue comes from its home market of North America, with none of the other 100 countries the company sells into representing a significant share. McDonald's is Lamb Weston's single-largest customer at 15% of fiscal 2025 sales, with no other company representing more than 10%. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.